Assessment and management of connective tissue disease-associated interstitial lung disease

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 32, Issue 1, 2015, Pages 2-21

  Chartrand, Sandra ^a,b   Fischer, Aryeh ^a  

^a DEPARTMENT OF MEDICINE   (United States)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Collagen vascular disease; Connective tissue disease; Interstitial lung disease; Interstitial pneumonia; Pulmonary fibrosis

Indexed keywords

AZATHIOPRINE; CALCINEURIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; RITUXIMAB;

ARTICLE; CLINICAL EVALUATION; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; CORTICOSTEROID THERAPY; EVIDENCE BASED PRACTICE; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; INTERVENTION STUDY; LUNG FUNCTION; LUNG TRANSPLANTATION; PNEUMOCYSTIS; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; TREATMENT PLANNING; ADULT; AGED; CONNECTIVE TISSUE DISEASES; DISEASE MANAGEMENT; FEMALE; INCIDENCE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; COMBINED MODALITY THERAPY; COMORBIDITY; CONNECTIVE TISSUE DISEASES; DISEASE MANAGEMENT; FEMALE; HUMANS; INCIDENCE; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84939121375     PISSN: 11240490     EISSN: 2532179X     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Solomon JJ, Fischer A. Idiopathic interstitial pneumonia and connective tissue disease-associated interstitial lung diseases: similarities and differences. In: Meyer KC, Nathan SD, editors. Idiopathic pulmonary fibrosis : a comprehensive clinical guide. 1st ed. New York, NY: Springer; 2014. p. xv, 451 pages.
2. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2012;51(6):1017-26. Epub 2011/09/09. doi: 10.1093/rheumatology/ker269. PubMed PMID: 21900368.
3. Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy. A long-term follow up. Clinical and experimental rheumatology. 2014. Epub 2014/01/23. PubMed PMID: 24447373.
4. Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmunity reviews. 2013;12 (11):1076-84. Epub 2013/05/21. doi: 10.1016/j.autrev.2013.05.001. PubMed PMID: 23684699.
5. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. American journal of respiratory and critical care medicine. 2002;165(2):277-304. Epub 2002/01/16. doi: 10.1164/ajrccm.165.2.ats01. PubMed PMID: 11790668.
6. Olson AL, Brown KK, Fischer A. Connective tissue disease-associated lung disease. Immunology and allergy clinics of North America. 2012; 32(4): 513-36. Epub 2012/10/30. doi: 10.1016/j.iac.2012.09.002. PubMed PMID: 23102064.
7. Cottin V. Significance of connective tissue diseases features in pulmonary fibrosis. European respiratory review : an official journal of the European Respiratory Society. 2013;22(129):273-80. Epub 2013/09/03. doi: 10.1183/09059180.00003013. PubMed PMID: 23997055.
8. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. American journal of respiratory and critical care medicine. 2012;185(11):1147-53. Epub 2012/03/01. doi: 10.1164/rccm.201108-1420PP. PubMed PMID: 22366047; PubMed Central PMCID: PMC3373068.
9. Fischer A, Richeldi L. Cross-disciplinary collaboration in connective tissue disease-related lung disease. Seminars in respiratory and critical care medicine. 2014;35(2):159-65. Epub 2014/03/29. doi: 10.1055/s-0034-1371530. PubMed PMID: 24668532.
10. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis and rheumatism. 2007;56(6):2005-12. Epub 2007/05/29. doi: 10.1002/art.22696. PubMed PMID: 17530640.
11. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. American journal of respiratory and critical care medicine. 2008;177(1):91-8. Epub 2007/09/29. doi: 10.1164/rccm.200705-655OC. PubMed PMID: 17901414; PubMed Central PMCID: PMC2176114.
12. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. American journal of respiratory and critical care medicine. 2002;165(12):1581-6. Epub 2002/06/19. doi: 10.1164/rccm.2106012. PubMed PMID: 12070056.
13. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. American journal of respiratory and critical care medicine. 2007;175(7):705-11. Epub 2007/01/16. doi: 10.1164/rccm.200607-912OC. PubMed PMID: 17218621.
14. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009;103(8):1152-8. PubMed PMID: 19304475.
15. Castelino FV, Goldberg H, Dellaripa PF. The impact of rheumatological evaluation in the management of patients with interstitial lung disease. Rheumatology (Oxford). 2011;50(3):489-93. PubMed PMID: 20685802.
16. Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest. 2006;130(4):976-81. Epub 2006/10/13. doi: 10.1378/chest.130.4.976. PubMed PMID: 17035427.
17. Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respiratory medicine. 2009;103(11):1719-24. Epub 2009/06/06. doi: 10.1016/j.rmed.2009.05.001. PubMed PMID: 19497723; PubMed Central PMCID: PMC2857337.
18. Fischer A, Du Bois RM. A practical approach to connective tissue disease-associated lung disease. In: Baughman RP, Du Bois RM, editors. Diffuse lung disease : a practical approach. 2nd ed. New York, NY: Springer; 2012. p. xii, 400 p.
19. Swigris JJ, Yorke J, Sprunger DB, Swearingen C, Pincus T, du Bois RM, et al. Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respiratory medicine. 2010; 104(9): 1350-5. Epub 2010/05/18. doi: 10.1016/j.rmed.2010.03.027. PubMed PMID: 20471238; PubMed Central PMCID: PMC2914213.
20. Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. American journal of respiratory and critical care medicine. 2005; 171(10): 1150-7. Epub 2005/01/11. doi: 10.1164/rccm.200405-578OC. PubMed PMID: 15640367.
21. Hallstrand TS, Boitano LJ, Johnson WC, Spada CA, Hayes JG, Raghu G. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. The European respiratory journal. 2005; 25(1): 96-103. Epub 2005/01/11. doi: 10.1183/09031936.04.00137203. PubMed PMID: 15640329.
22. Buch MH, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells AU, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Annals of the rheumatic diseases. 2007; 66(2): 169-73. Epub 2006/07/27. doi: 10.1136/ard.2006.054866. PubMed PMID: 16868020; PubMed Central PMCID: PMC1798506.
23. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. American journal of respiratory and critical care medicine. 2008;177(11):1248-54. Epub 2008/03/29. doi: 10.1164/rccm.200706-877OC. PubMed PMID: 18369202.
24. Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Predictors of progression of HRCT diagnosed fibrosing alveolitis in patients with rheumatoid arthritis. Annals of the rheumatic diseases. 2002;61(6):517-21. Epub 2002/05/15. PubMed PMID: 12006324; PubMed Central PMCID: PMC1754108.
25. Lynch DA. Quantitative computed tomography of diffuse lung disease. Journal of thoracic imaging. 2013;28(5):264-5. Epub 2013/08/24. doi: 10.1097/RTI.0b013e3182a14fd8. PubMed PMID: 23966091.
26. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. American journal of respiratory and critical care medicine. 2003;168(5):543-8. Epub 2003/05/30. doi: 10.1164/rccm.200209-1112OC. PubMed PMID: 12773329.
27. Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis and rheumatism. 2005;53(4):549-57. Epub 2005/08/06. doi: 10.1002/art.21322. PubMed PMID: 16082627.
28. Lynch DA. Quantitative CT of fibrotic interstitial lung disease. Chest. 2007; 131(3): 643-4. Epub 2007/03/16. doi: 10.1378/chest.06-2955. PubMed PMID: 17356073.
29. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis and rheumatism. 1997;40(10):1829-37. Epub 1997/10/23. doi: 10.1002/1529-0131(199710) 40:10< 1829::AID-ART16>3.0.CO;2-T. PubMed PMID: 9336418.
30. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis care & research. 2012;64(5):625-39. Epub 2012/04/05. doi: 10.1002/acr.21641. PubMed PMID: 22473917.
31. Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. The Journal of rheumatology. 2012;39(8):1559-82. Epub 2011/09/17. doi: 10.3899/jrheum.110207. PubMed PMID: 21921096.
32. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the rheumatic diseases. 2014;73(3):492-509. Epub 2013/10/29. doi: 10.1136/annrheumdis-2013-204573. PubMed PMID: 24161836; PubMed Central PMCID: PMC3933074.
33. Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. British journal of rheumatology. 1989;28(2):147-53. Epub 1989/04/01. PubMed PMID: 2706419.
34. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax. 1992;47(8):628-33. Epub 1992/08/01. PubMed PMID: 1412121; PubMed Central PMCID: PMC463926.
35. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. The Journal of rheumatology. 1995;22(6):1043-7. Epub 1995/06/01. PubMed PMID: 7674228.
36. Searles G, McKendry RJ. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. The Journal of rheumatology. 1987;14(6):1164-71. Epub 1987/12/01. PubMed PMID: 3325643.
37. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nature reviews Rheumatology. 2009;5(10):578-82. Epub 2009/10/03. doi: 10.1038/nrrheum.2009.181. PubMed PMID: 19798034.
38. Karampetsou MP, Liossis SN, Sfikakis PP. TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future. QJM : monthly journal of the Association of Physicians. 2010; 103(12): 917-28. Epub 2010/08/31. doi: 10.1093/qjmed/hcq152. PubMed PMID: 20802008.
39. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004; 38(9): 1261-5. Epub 2004/05/06. doi: 10.1086/383317. PubMed PMID: 15127338.
40. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124-31. Epub 2010/08/03. doi: 10.1093/rheumatology/keq242. PubMed PMID: 20675706; PubMed Central PM-CID: PMC3105607.
41. Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Annals of the rheumatic diseases. 2011;70(4):616-23. Epub 2010/12/24. doi: 10.1136/ard.2010.137422. PubMed PMID: 21177290.
42. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology (Oxford). 2011;50(12):2297-305. Epub 2011/10/25. doi: 10.1093/rheumatology/ker289. PubMed PMID: 22019799.
43. Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Current opinion in pulmonary medicine. 2011;17(5):362-7. Epub 2011/05/21. doi: 10.1097/MCP.0b013e3283483ea5. PubMed PMID: 21597375.
44. Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2013. Epub 2013/11/30. doi: 10.1111/resp.12214. PubMed PMID: 24286447.
45. Ando K, Motojima S, Doi T, Nagaoka T, Kaneko N, Aoshima M, et al. Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respiratory investigation. 2013;51(2):69-75. Epub 2013/06/26. doi: 10.1016/j.resinv.2012.12.002. PubMed PMID: 23790734.
46. Horai Y, Isomoto E, Koga T, Okada A, Kawashiri SY, Tamai M, et al. Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern rheumatology / the Japan Rheumatism Association. 2013;23(1):190-4. Epub 2012/03/31. doi: 10.1007/s10165-012-0637-6. PubMed PMID: 22460910.
47. Steen VD, Medsger TA, Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis and rheumatism. 1998;41(9):1613-9. Epub 1998/09/29. doi: 10.1002/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O. PubMed PMID: 9751093.
48. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. The Journal of rheumatology. 1993;20(5):838-44. Epub 1993/05/01. PubMed PMID: 8336309.
49. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis and rheumatism. 1998;41(7):1215-20. Epub 1998/07/15. doi: 10.1002/1529-0131(199807)41:7<1215::AID-ART11>3.0.CO;2-Y. PubMed PMID: 9663478.
50. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis and rheumatism. 1994;37(5):729-35. Epub 1994/05/01. PubMed PMID: 8185701.
51. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Annals of internal medicine. 2000;132(12):947-54. Epub 2000/06/17. PubMed PMID: 10858177.
52. Steen VD, Lanz JK, Jr., Conte C, Owens GR, Medsger TA, Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis and rheumatism. 1994;37(9):1290-6. Epub 1994/09/01. PubMed PMID: 7945491.
53. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. The New England journal of medicine. 2006;354(25):2655-66. Epub 2006/06/23. doi: 10.1056/NEJ-Moa055120. PubMed PMID: 16790698.
54. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. American journal of respiratory and critical care medicine. 2007;176(10):1026-34. Epub 2007/08/25. doi: 10.1164/rccm.200702-326OC. PubMed PMID: 17717203; PubMed Central PMCID: PMC2078679.
55. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. Chest. 2009;136(5):1333-40. Epub 2009/11/07. doi: 10.1378/chest.09-0108. PubMed PMID: 19892673; PubMed Central PMCID: PMC2773360.
56. Roth MD, Tseng CH, Clements PJ, Furst DE, Tashkin DP, Goldin JG, et al. Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis and rheumatism. 2011; 63(9): 2797-808. Epub 2011/05/07. doi: 10.1002/art.30438. PubMed PMID: 21547897; PubMed Central PMCID: PMC3910296.
57. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis and rheumatism. 2006;54(12):3962-70. Epub 2006/11/30. doi: 10.1002/art.22204. PubMed PMID: 17133610.
58. Mira-Avendano IC, Parambil JG, Yadav R, Arrossi V, Xu M, Chapman JT, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respiratory medicine. 2013;107(6): 890-6. Epub 2013/03/23. doi: 10.1016/j.rmed.2013.02.015. PubMed PMID: 23517887.
59. Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124-30. Epub 2006/06/07. doi: 10.1093/rheumatology/kel112. PubMed PMID: 16754626.
60. Berezne A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. The Journal of rheumatology. 2008;35(6): 1064-72. Epub 2008/05/09. PubMed PMID: 18464307.
61. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clinical rheumatology. 2004;23(4):306-9. Epub 2004/08/05. doi: 10.1007/s10067-004-0906-7. PubMed PMID: 15293090.
62. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest. 2006; 130(1): 30-6. Epub 2006/07/15. doi: 10.1378/chest.130.1.30. PubMed PMID: 16840379.
63. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-8. Epub 2006/02/24. doi: 10.1093/rheumatology/kei211. PubMed PMID: 16490756.
64. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008; 133(2): 455-60. Epub 2007/12/12. doi: 10.1378/chest.06-2861. PubMed PMID: 18071023.
65. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clinical rheumatology. 2010; 29(10): 1167-8. Epub 2010/06/10. doi: 10.1007/s10067-010-1498-z. PubMed PMID: 20532938.
66. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respiratory medicine. 2008;102(1): 150-5. Epub 2007/09/08. doi: 10.1016/j.rmed.2007.07.021. PubMed PMID: 17822892.
67. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. The Journal of rheumatology. 2013;40(5):640-6. Epub 2013/03/05. doi: 10.3899/jrheum.121043. PubMed PMID: 23457378; PubMed Central PMCID: PMC3676865.
68. Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity. 2005;38(5):383-92. Epub 2005/10/18. doi: 10.1080/08916930500124023. PubMed PMID: 16227154.
69. Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clinical rheumatology. 2011;30(8):1021-8. Epub 2011/02/23. doi: 10.1007/s10067-011-1713-6. PubMed PMID: 21340495.
70. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis and rheumatism. 2005;52(8):2439-46. Epub 2005/07/30. doi: 10.1002/art.21240. PubMed PMID: 16052580.
71. Ochi S, Nanki T, Takada K, Suzuki F, Komano Y, Kubota T, et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clinical and experimental rheumatology. 2005; 23(5): 707-10. Epub 2005/09/22. PubMed PMID: 16173253.
72. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762-3. Epub 1999/05/29. doi: 10.1016/S0140-6736(99)01927-3. PubMed PMID: 10347992; PubMed Central PMCID: PMC2977932.
73. Braun-Moscovici Y, Butbul-Aviel Y, Guralnik L, Toledano K, Markovits D, Rozin A, et al. Rituximab: rescue therapy in lifethreatening complications or refractory autoimmune diseases: a single center experience. Rheumatology international. 2013; 33(6): 1495-504. Epub 2012/12/15. doi: 10.1007/s00296-012-2587-x. PubMed PMID: 23239037.
74. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010;363(3):221-32. Epub 2010/07/22. doi: 10.1056/NEJ-Moa0909905. PubMed PMID: 20647199; PubMed Central PM-CID: PMC3137658.
75. Tony HP, Burmester G, Schulze-Koops H, Grunke M, Henes J, Kotter I, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis research & therapy. 2011;13(3):R75. Epub 2011/05/17. doi: 10.1186/ar3337. PubMed PMID: 21569519; PubMed Central PMCID: PMC3218885.
76. Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology (Oxford). 2009; 48(8):968-71. Epub 2009/06/18. doi: 10.1093/rheumatology/kep157. PubMed PMID: 19531628.
77. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. The European respiratory journal. 2012;40(3): 641-8. Epub 2012/01/28. doi: 10.1183/09031936.00163911. PubMed PMID: 22282550.
78. Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis and rheumatism. 2009;60(2):578-83. Epub 2009/01/31. doi: 10.1002/art.24249. PubMed PMID: 19180481; PubMed Central PMCID: PMC2637937.
79. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271-80. Epub 2009/05/19. doi: 10.1093/rheumatology/kep093. PubMed PMID: 19447770; PubMed Central PMCID: PMC2806066.
80. Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Paliogianni F, Sirinian C, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clinical and experimental rheumatology. 2012;30(2 Suppl 71):S17-22. Epub 2012/01/17. PubMed PMID: 22244622.
81. Moazedi-Fuerst F, Kielhauser S, Brickmann K, Hermann J, Lutfi A, Meilinger M, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scandinavian journal of rheumatology. 2014. Epub 2014/03/13. doi: 10.3109/03009742.2013.869617. PubMed PMID: 24611681.
82. Matteson E, Bongartz T, Ryu J, Crowson C, Hartman T, Dellaripa PF. Open-Label, Pilot Study of the Safety and Clinical Effects of Rituximab in Patients with Rheumatoid Arthritis-Associated Interstitial Pneumonia. Open Journal of Rheumatology and Autoimmune Diseases. 2012;2(3):53-8. doi: 10.4236/ojra.2012.23011.
83. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. The New England journal of medicine. 2012;367(21):2015-25. Epub 2012/11/23. doi: 10.1056/NEJMra1009433. PubMed PMID: 23171098.
84. Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187(3):201-6. Epub 2009/04/24. doi: 10.1007/s00408-009- 9146-6. PubMed PMID: 19387736.
85. Johnson-Warrington V, Williams J, Bankart J, Steiner M, Morgan M, Singh S. Pulmonary rehabilitation and interstitial lung disease: aiding the referral decision. Journal of cardiopulmonary rehabilitation and prevention. 2013;33(3):189-95. Epub 2013/04/19. doi: 10.1097/HCR.0b013e31828db112. PubMed PMID: 23595005.
86. Bye PT, Anderson SD, Woolcock AJ, Young IH, Alison JA. Bicycle endurance performance of patients with interstitial lung disease breathing air and oxygen. The American review of respiratory disease. 1982; 126(6):1005-12. Epub 1982/12/01. PubMed PMID: 7181219.
87. Harris-Eze AO, Sridhar G, Clemens RE, Gallagher CG, Marciniuk DD. Oxygen improves maximal exercise performance in interstitial lung disease. American journal of respiratory and critical care medicine. 1994;150(6 Pt 1):1616-22. Epub 1994/12/01. doi: 10.1164/ajrccm.150.6.7952624. PubMed PMID: 7952624.
88. Visca D, Montgomery A, de Lauretis A, Sestini P, Soteriou H, Maher TM, et al. Ambulatory oxygen in interstitial lung disease. The European respiratory journal. 2011;38(4):987-90. Epub 2011/10/04. doi: 10.1183/09031936.00190710. PubMed PMID: 21965506.
89. Ntoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Seminars in arthritis and rheumatism. 2006;36(3):173-81. Epub 2006/10/19. doi: 10.1016/j.semarthrit.2006.08.002. PubMed PMID: 17045629.
90. Fagundes MN, Caleiro MT, Navarro-Rodriguez T, Baldi BG, Kavakama J, Salge JM, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respiratory medicine. 2009; 103(6): 854-60. Epub 2009/02/10. doi: 10.1016/j.rmed.2008.12.018. PubMed PMID: 19201182.
91. Miura Y, Fukuda K, Maeda T, Kurosaka M. Gastroesophageal reflux disease in patients with rheumatoid arthritis. Modern rheumatology / the Japan Rheumatism Association. 2014;24(2):291-5. Epub 2013/11/21. doi: 10.3109/14397595.2013.843749. PubMed PMID: 24252041.
92. Mandl T, Ekberg O, Wollmer P, Manthorpe R, Jacobsson LT. Dysphagia and dysmotility of the pharynx and oesophagus in patients with primary Sjogren's syndrome. Scandinavian journal of rheumatology. 2007; 36(5): 394-401. Epub 2007/10/27. doi: 10.1080/03009740701607638. PubMed PMID: 17963171.
93. Gaal J, Varga J, Szabados L, Garai I, Galuska L, Suranyi P, et al. High prevalence of oesophageal involvement in patients with undifferentiated connective tissue disease using radionuclide oesophageal transit scintigraphy. Nuclear medicine communications. 2005; 26(12): 1113-7. Epub 2005/11/03. PubMed PMID: 16264359.
94. Bredenoord AJ, Pandolfino JE, Smout AJ. Gastro-oesophageal reflux disease. Lancet. 2013;381(9881):1933-42. Epub 2013/03/13. doi: 10.1016/S0140-6736(12)62171-0. PubMed PMID: 23477993.
95. Weinstein WM, Kadell BM. The Gastrointestinal Tract in Systemic Sclerosis. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia, PA: Lipincott Williams & Wilkins; 2004. p. xvii, 430 p.
96. Nathan SD, Hassoun PM. Pulmonary hypertension due to lung disease and/or hypoxia. Clinics in chest medicine. 2013;34(4):695-705. Epub 2013/11/26. doi: 10.1016/j.ccm.2013.08.004. PubMed PMID: 24267299.
97. Ahmed S, Palevsky HI. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheumatic diseases clinics of North America. 2014;40(1):103-24. Epub 2013/11/26. doi: 10.1016/j.rdc.2013.10.001. PubMed PMID: 24268012.
98. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. American journal of respiratory and critical care medicine. 2003;167(5):735-40. Epub 2002/12/14. doi: 10.1164/rccm.200210-1130OC. PubMed PMID: 12480614.
99. Steen V, Medsger TA, Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis and rheumatism. 2003;48(2):516-22. Epub 2003/02/07. doi: 10.1002/art.10775. PubMed PMID: 12571862.
100. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis and rheumatism. 2008;58(1):284-91. Epub 2008/01/01. doi: 10.1002/art.23187. PubMed PMID: 18163505.
101. Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis research & therapy. 2010;12(4):213. Epub 2010/08/26. doi: 10.1186/ar3097. PubMed PMID: 20735863; PubMed Central PMCID: PMC2945045.
102. Shahane A. Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis. Rheumatology international. 2013; 33(7): 1655-67. Epub 2013/01/22. doi: 10.1007/s00296-012-2659-y. PubMed PMID: 23334373.
103. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. American journal of respiratory and critical care medicine. 1999; 160(2): 600-7. Epub 1999/08/03. doi: 10.1164/ajrccm.160.2.9810008. PubMed PMID: 10430735.
104. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Current opinion in pulmonary medicine. 2003;9(5):426-30. Epub 2003/08/09. PubMed PMID: 12904715.
105. Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis and rheumatism. 2011;63(8):2456-64. Epub 2011/05/04. doi: 10.1002/art.30423. PubMed PMID: 21538327.
106. Solomon JJ, Fischer A. Connective Tissue Disease-Associated Interstitial Lung Disease: A Focused Review. Journal of intensive care medicine. 2013. Epub 2013/12/29. doi: 10.1177/0885066613516579. PubMed PMID: 24371251.
107. Bridges CB, Coyne-Beasley T. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older: United States, 2014. Annals of internal medicine. 2014;160(3):190. Epub 2014/03/25. doi: 10.7326/M13-2826. PubMed PMID: 24658695.
108. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the rheumatic diseases. 2011;70(3):414-22. Epub 2010/12/07. doi: 10.1136/ard.2010.137216. PubMed PMID: 21131643.
109. Bombardier C, Hazlewood GS, Akhavan P, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. The Journal of rheumatology. 2012;39(8):1583-602. Epub 2012/06/19. doi: 10.3899/jrheum.120165. PubMed PMID: 22707613.
110. Veetil BM, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis care & research. 2013; 65(6): 854-61. Epub 2013/01/03. doi: 10.1002/acr.21928. PubMed PMID: 23281295; PubMed Central PMCID: PMC3674119.
111. Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013; 22(3): 238-44. Epub 2012/12/22. doi: 10.1177/0961203312470186. PubMed PMID: 23257402.
112. Zhang J, Delzell E, Xie F, Baddley JW, Spettell C, McMahan RM, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis research & therapy. 2011;13(5):R174. Epub 2011/10/26. doi: 10.1186/ar3497. PubMed PMID: 22024532; PubMed Central PMCID: PMC3308109.
113. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2002;34(8):1098-107. Epub 2002/03/27. doi: 10.1086/339548. PubMed PMID: 11914999.
114. Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N, Nishinarita M. Evaluation of Pneumocystis pneumonia infection risk factors in patients with connective tissue disease. Modern rheumatology / the Japan Rheumatism Association. 2006;16(5):282-8. Epub 2006/10/14. doi: 10.1007/s10165-006-0502-6. PubMed PMID: 17039308.
115. Sowden E, Carmichael AJ. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC infectious diseases. 2004;4:42. Epub 2004/10/19. doi: 10.1186/1471-2334-4-42. PubMed PMID: 15488151; PubMed Central PMCID: PMC526257.
116. Vananuvat P, Suwannalai P, Sungkanuparph S, Limsuwan T, Ngamjanyaporn P, Janwityanujit S. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases. Seminars in arthritis and rheumatism. 2011;41(3):497-502. Epub 2011/10/01. doi: 10.1016/j.semarthrit.2011.05.004. PubMed PMID: 21959291.
117. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. June, 2000. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2005;20(8):1487-94; discussion 6. Epub 2005/09/09. doi: 10.1359/jbmr.2005.20.8.1486. PubMed PMID: 16149171.
118. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis care & research. 2010;62(11):1515-26. Epub 2010/07/28. doi: 10.1002/acr.20295. PubMed PMID: 20662044.
119. Schachna L, Medsger TA, Jr., Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension. Arthritis and rheumatism. 2006;54(12):3954-61. Epub 2006/11/30. doi: 10.1002/art.22264. PubMed PMID: 17133609.
120. Saggar R, Khanna D, Furst DE, Belperio JA, Park GS, Weigt SS, et al. Systemic sclerosis and bilateral lung transplantation: a single centre experience. The European respiratory journal. 2010;36(4):893-900. Epub 2010/03/31. doi: 10.1183/09031936.00139809. PubMed PMID: 20351032; PubMed Central PMCID: PMC2921556.